2-溴-5-甲氧基吡啶 | 105170-27-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-溴-5-甲氧基吡啶
• 中文别名: 2-溴-5-甲氧吡啶；5-甲氧基-2-溴吡啶
• 英文名称: 2-bromo-5-methoxypyridine
• CAS: 105170-27-2
• 化学式: C₆H₆BrNO
• mdl: MFCD07781221
• 分子量: 188.024
• InChiKey: WULVUFYZVYHTFX-UHFFFAOYSA-N

物化性质

• 熔点：
  22 °C
• 沸点：
  113 °C(Press: 59 Torr)
• 密度：
  1.530±0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温下，使用了惰性气体。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-5-methoxypyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-5-methoxypyridine
CAS number: 105170-27-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6BrNO
Molecular weight: 188.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

2-溴-5-甲氧基吡啶是一种杂环类衍生物，可用作有机合成中间体。

该化合物可通过以下方法制备：首先由2,5-二溴吡啶为原料，制备得到2-溴-5-羟基吡啶，再通过甲基化反应得到2-溴-5-甲氧基吡啶。

具体步骤如下： 在氩气气氛下，将15毫升DMF中搅拌溶解的含有155毫克6.5毫摩尔NaH的溶液冷却至0°C。然后加入972毫克（5.4毫米摩尔）2-溴-5-羟基吡啶与10毫升DMF的混合液。在该温度下搅拌1小时后，缓慢滴加0.4毫升碘甲烷（6.5毫摩尔），并在室温下继续搅拌1小时。通过加入少量饱和NH₄Cl水溶液淬灭反应，并分离有机层。使用乙酸乙酯萃取3次，用水和盐水洗涤，用Na₂SO₄干燥后浓缩。所得液体通过Kugelrohr蒸馏纯化，最终得到2-溴-5-甲氧基吡啶690毫克（3.7毫米摩尔），产率68%。

反应信息

• 作为反应物：
  描述：

  2-溴-5-甲氧基吡啶 在 Ni(PPh3)2 、 四乙基碘化铵 、 锌 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 以87%的产率得到5,5-二甲氧基-2,2-联吡啶
  参考文献：
  名称：

  带有3，3′-亚芳基双丙烯酰基作为接头的新型癸二环丙烷[c]吡咯并[3，2-e]吲哚双烷基化剂。

  摘要：

  我们合成了新型山高环丙烷[c]吡咯并[3,2-e]吲哚（CPI）双烷基化剂并评估了其抗肿瘤活性。在这些衍生物中，发现其中11a（AT-760）的两个Seco 3-甲氧基羰基-2-三氟甲基CPI（MCTFCPI）部分与3,3'-（1,4-亚苯基）双丙烯酰基相连。分别对HeLaS3人子宫颈癌细胞和结肠26腺癌细胞具有比8（bizelesin，U-77,779）更强的细胞毒性和抗肿瘤活性。还显示出与化合物8或丝裂霉素C（MMC）相比，化合物11a在人结肠CX-1模型中表现出改善的体内功效。发现11a的有效剂量比8a的有效剂量低2倍。

  DOI：

  10.1021/jm000107x
• 作为产物：
  描述：

  2,5-二溴吡啶 在 正丁基锂 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.75h， 生成 2-溴-5-甲氧基吡啶
  参考文献：
  名称：

  9,9'-螺二芴和4,5-Diaza-9,9'-螺二芴的合成及其作为石英微天平亲和材料的应用。

  摘要：

  已经合成了两种不同类型的9，9′-螺二芴的氮杂类似物。这些可以通过为螺二芴提供额外的吡啶基部分或通过将氮杂官能团直接安装到螺二芴核中而获得。然后，将这些结构刚性的化合物评估为石英微天平的亲和材料，并证明对检测挥发性有机化合物具有很高的效力。

  DOI：

  10.1002/cplu.201700105

文献信息

• [EN] ROR-GAMMA INHIBITORS<br/>[FR] INHIBITEURS DE ROR-GAMMA
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019063748A1

  公开（公告）日：2019-04-04

  The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

  本发明涉及公式I的化合物和包含公式I化合物的药物组合物。公式I的化合物在治疗由RORγ介导的炎症性、代谢性或自身免疫性疾病方面是有用的。
• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS D'HISTONES DÉMÉTHYLASES
  申请人：CHRYSALIS INC

  公开号：WO2017143011A1

  公开（公告）日：2017-08-24

  This disclosure relates to compounds that inhibit histone demethylase activity. In particular, the disclosure relates to compounds that inhibit histone lysine demethylase KDM5B, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions disclosed herein.

  这份披露涉及抑制组蛋白去甲基化酶活性的化合物。具体而言，该披露涉及抑制组蛋白赖氨酸去甲基化酶KDM5B的化合物，以及使用这些化合物和药物组合物的方法，例如使用本文披露的化合物和药物组合物治疗癌症的方法。
• Synthesis of Pyridylsulfonium Salts and Their Application in the Formation of Functionalized Bipyridines
  作者：Vincent K. Duong、Alexandra M. Horan、Eoghan M. McGarrigle

  DOI：10.1021/acs.orglett.0c03048

  日期：2020.11.6

  arylation of pyridylsulfides with good functional group tolerance was developed. To demonstrate synthetic utility, the resulting pyridylsulfonium salts were used in a scalable transition-metal-free coupling protocol, yielding functionalized bipyridines with extensive functional group tolerance. This modular methodology permits selective introduction of functional groups from commercially available pyridyl

  开发了具有良好官能团耐受性的吡啶基硫醚的S选择性芳基化反应。为了证明其合成实用性，将所得吡啶基yl盐用于可扩展的无过渡金属偶联方案中，得到具有广泛官能团耐受性的官能化联吡啶。该模块化方法允许从可商购的吡啶基卤中选择性引入官能团，从而提供对称和不对称的2,2'-和2,3'-联吡啶。该方法的迭代应用使得能够合成具有三种不同吡啶组分的官能化的吡啶。
• [EN] COMPOUNDS USEFUL AS CSF1 MODULATORS<br/>[FR] COMPOSÉS UTILES EN TANT QUE MODULATEURS DU FACTEUR 1 DE STIMULATION DE COLONIES
  申请人：REDX PHARMA PLC

  公开号：WO2016051193A1

  公开（公告）日：2016-04-07

  This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

  这项发明涉及新颖化合物以及包含这些新颖化合物的药物组合物。更具体地，该发明涉及用作集落刺激因子1受体（cFMS）调节剂（例如cFMS抑制剂）的化合物。这项发明还涉及制备这些化合物的方法，这些化合物在治疗中的用途以及利用这些化合物进行治疗的方法。具体而言，该发明涉及利用这些化合物治疗癌症和自身免疫性疾病。
• [EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2017214505A1

  公开（公告）日：2017-12-14

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物、以及使用这种化合物治疗或预防与酶神经鞘糖脂转移酶（CGT）相关的疾病或紊乱的方法，例如溶酶体贮积症。溶酶体贮积症的例子包括 Krabbe 病和白质变性白血病。